NEW YORK (GenomeWeb News) – SDIX reported after the close of the market on Wednesday that its second-quarter revenues fell 10 percent year over year.

The Newark, Del.-based company said that for the three months ended June 30, revenues totaled $5.5 million, down from $6.1 million a year ago. The drop-off was primarily related to the timing of in vitro diagnostic sales, it said, as well as continued weakness in the biopharmaceutical market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.